Stock listing

ASX:CHM Chimeric Therapeutics Limited Share Price

Home listing (ASX) of Chimeric Therapeutics Limited

Follow Chimeric Therapeutics Limited into a list and get an email when it puts out news.

Share price · ASX:CHM

$0.0030 AUD 0.0000 (0.0%)

Close on Nov 19, 2026

Past year -99.0% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.0030 – $0.0030 AUDNov 19, 2026
Market cap
$442,386 AUDAt the close on Nov 19, 2026 · price × 147.5M shares outstanding
52-week range
$0.0030 – $0.4000 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$11,148 AUDMedian day 0 shares · 37 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Chimeric Therapeutics Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:CHM · Home$0.0030 AUD0.0000 (0.0%)—$0.0030$0.0030$0.0030$0.0030Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:CHM · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.0030-0.0020-40.0%$0.0040$0.0040$0.003025,127,056
$0.0050+0.0010+25.0%$0.0040$0.0050$0.0040905,234
$0.0040-0.0010-20.0%$0.0050$0.0050$0.0040780,031
$0.0050+0.0010+25.0%$0.0040$0.0050$0.0040511,864
$0.0040-0.0010-20.0%$0.0050$0.0050$0.00403,645,258
$0.0050-0.0010-16.7%$0.0060$0.0060$0.005013,378,075
$0.0060-0.0010-14.3%$0.0070$0.0070$0.00601,350,110
$0.0070+0.0010+16.7%$0.0060$0.0075$0.00601,431,073
$0.00600.00000.0%$0.0060$0.0060$0.0060150,611
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0070$0.0060935,871
$0.0060-0.0010-14.3%$0.0060$0.0060$0.006021,448
$0.0070-0.0010-12.5%$0.0080$0.0080$0.007067,857
$0.00800.00000.0%$0.0080$0.0080$0.0080108,734
$0.0080+0.0010+14.3%$0.0070$0.0080$0.007066,240
$0.00700.00000.0%$0.0070$0.0070$0.00701,231,577
$0.0070+0.0010+16.7%$0.0060$0.0070$0.00601,760,880
$0.0060-0.0020-25.0%$0.0090$0.0090$0.00605,378,282
$0.0080-0.0030-27.3%$0.0110$0.0110$0.00803,354,346
$0.0110-0.0010-8.3%$0.0110$0.0110$0.01102,858
$0.01200.00000.0%$0.0120$0.0120$0.011017,546
$0.0120+0.0010+9.1%$0.0110$0.0120$0.011043,133
$0.0110+0.0020+22.2%$0.0090$0.0110$0.00902,033,701
$0.0090-0.0010-10.0%$0.0100$0.0100$0.00905,414,073
$0.0100-0.0010-9.1%$0.0110$0.0115$0.01002,011,389
$0.0110-0.0020-15.4%$0.0130$0.0140$0.01101,873,645
$0.0130-0.0020-13.3%$0.0160$0.0160$0.01302,466,882
$0.0150-0.0050-25.0%$0.0180$0.0180$0.01502,673,341
$0.0200+0.0020+11.1%$0.0190$0.0200$0.01704,427,792
$0.0180-0.0010-5.3%$0.0200$0.0200$0.01801,747,308
$0.0190-0.0160-45.7%$0.0180$0.0220$0.01408,864,321

Splits

1 split · ASX:CHM · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
Ticker
ASX:CHM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Chimeric Therapeutics Limited news

Chimeric Therapeutics Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 129 in all · newest Oct 30, 2026 · oldest 2021
Decks
23 decks · latest Jul 28, 2026

Where Chimeric Therapeutics Limited is listed

ListingExchangeCountryCurrency
ASX:CHM · Home listing · This pageASXAustraliaAUD
OTC:CHMMFOTCUnited StatesUSD

Valuation

EV/sales −0.1× against a median of 0.3×: the lowest of 3 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · price Nov 19, 2026

Enterprise value
−$332,667 AUD
P/E
Loss
EV/sales
−0.1×
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
78.7%
Operating margin
−380.8%
Net margin
−262.8%
Debt to equity
2.5×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,500−US$4,0701.2×n/an/a0.4×n/a0.0×-0.16
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Median of the othersUS$292,268US$73,5101.2×0.3×0.1×−341.6%0.0×1.22

Team and board

Officers

OfficerRole
Rebecca McQualterChief Executive Officer
Agathe BourgogneHead of Manufacturing
Stephanie H AstrowChief Scientific Officer

Board

DirectorRole
Bradley GloverNon-executive Chair
Lesley RusselNon-Executive Director
Miles PrinceNon-Executive Director
Philip HainsNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 29, 20250.0%
Q2 2025Feb 28, 20250.0%
Q2 2023Feb 28, 2023 · Before open−4.3%
Q4 2022Sep 30, 2022 · Before open+1.1%
Q2 2022Feb 27, 2022 · After close0.0%
Q4 2021Aug 30, 2021 · After close0.0%
Q2 2021Feb 26, 2021 · After close+1.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck19 slidesJul 28, 2026
Investor Presentation (March 2026)Investor deck18 slidesMar 25, 2026
Shareholder Meeting (November 2025)Shareholder meeting7 slidesNov 25, 2025
Investor Presentation (October 2025)Investor deck24 slidesOct 8, 2025
Investor Presentation (September 2025)Investor deck18 slidesSep 9, 2025
Shareholder Meeting (July 2025)Shareholder meeting11 slidesJul 23, 2025
Investor Presentation (May 2025)Investor deck14 slidesMay 22, 2025
Shareholder Meeting (December 2024)Shareholder meeting11 slidesDec 4, 2024
Shareholder Meeting (November 2024)Shareholder meeting15 slidesNov 12, 2024
Investor Presentation (July 2024)Investor deck42 slidesJul 25, 2024
All 23 decks
DeckKindSlidesDate
Shareholder Meeting (June 2024)Shareholder meeting19 slidesJun 11, 2024
Investor Presentation (January 2024)Investor deck41 slidesJan 18, 2024
Shareholder Meeting (November 2023)Shareholder meeting13 slidesNov 14, 2023
Investor Presentation (October 2023)Investor deck32 slidesOct 25, 2023
Shareholder Meeting (September 2023)Shareholder meeting13 slidesSep 13, 2023
Shareholder Meeting (November 2022)Shareholder meeting24 slidesNov 15, 2022
Technical Presentation (March 2022)Technical16 slidesMar 7, 2022
Investor Presentation (February 2022)Investor deck44 slidesFeb 22, 2022
Corporate Update (December 2021)Corporate update26 slidesDec 1, 2021
Shareholder Meeting (November 2021)Shareholder meeting18 slidesNov 22, 2021
Corporate Update (November 2021)Corporate update14 slidesNovember 2021
ASCO 2021Conference7 slidesJun 4, 2021
Corporate Update (March 2021)Corporate update20 slidesMar 18, 2021

Open Decks

Financings

RaiseDateIn US dollars
Convertible notes with associated warrants
Tranche closed: A$650,000 raised
Use of proceeds: Support the ongoing Phase 1/2 clinical trial activities and general working capital
Jul 31, 2026US$456,561
Private placement of fully paid ordinary shares with 1-for-1 attaching options
Announced: A$4.4M · A$0.003 a share · Warrants at A$0.005 · PAC Partners Securities Pty Ltd +1
Dealers: PAC Partners Securities Pty Ltd (co-lead), Taylor Collison Limited (co-lead)
Buyers: US-based family office (US$2 M (~A$3 M) commitment)
Use of proceeds: CHM CDH17 CAR-T trial to end of Phase 1, CORE-NK clinical programs, working capital and offer costs
Dec 23, 2025US$2.94M
Convertible note
Announced: A$4M
Buyers: US institutional investor (A$4 M via Convertible Note)
Use of proceeds: Fund the CHM CDH17 CAR-T trial through Phase 1, including next patient cohort at an increased dose
Dec 23, 2025US$2.68M
Rights offering of new fully paid ordinary shares with attaching options
Closed: A$1M raised · 1 new attaching option for every New Share issued · PAC Partners +1
Dealers: PAC Partners (co-lead), Taylor Collison (co-lead)
Use of proceeds: Further runway to progress the company's programs
Apr 24, 2025US$639,490

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue3.97M7.46M4.51M2.62M2.65K0
Cost of revenue846.8K3.92K965.4K949.8K847.0K
Gross profit3.12M7.45M3.54M1.67M-844.3K
Research and development9.76M10.1M13.5M5.17M3.78M
Selling, general and administrative7.05M9.00M11.9M8.73M6.02M151.8K
Operating income-15.1M-12.3M-29.5M-14.6M-14.8M-64.0K
Depreciation and amortization1.03M1.01M965.4K949.8K847.0K153.6K
EBITDA-14.1M-11.3M-28.5M-13.6M-14.0M89.6K
Interest expense211.0K331.8K773.8K640.1K5.88K0
Income before tax-10.3M-16.3M-30.3M-15.7M-15.1M-64.0K
Income tax110.8K-3.75M92.8K163.7K-257.9K-153.6K
Net income-10.4M-12.5M-25.9M-15.9M-15.1M-64.0K
Earnings per share, basic-0.77-1.80-5.98-4.42-4.64-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents5.76M3.05M5.37M18.4M22.4M100
Receivables4.55M86.6K3.65M2.66M24.2K
Inventory1-882.1K
Current assets10.5M3.22M9.35M21.2M22.7M100
Property, plant and equipment5.60K16.0K13.6K
Total assets21.6M15.3M22.4M34.9M36.5M100
Accounts payable6.57M3.20M7.41M4.70M2.04M
Current liabilities14.6M10.1M14.7M9.02M7.35M64.0K
Long-term debt03.68M
Total debt3.59M3.68M34.0K
Total liabilities19.6M12.8M16.7M9.17M11.4M64.0K
Shareholders' equity1.97M2.47M5.66M25.7M25.1M-63.9K
Shares outstanding13.5M6.96M4.33M3.60M3.26M3.43M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-7.28M-7.54M-16.3M-13.2M-8.84M-34.0K
Capital spending-1-7.55M-112.2K-537.9K-5.31M-16.3K
Free cash flow-7.28M10.1K-16.4M-13.7M-14.1M-34.0K
Cash from investing-112.2K-577.9K-5.30M-5.31M
Cash from financing10.0M8.26M253.4K9.50M36.5M34.1K
Dividends paid-2.31M-4.05M
Share buybacks-572.0K-1.20M-88.8K-1.31M-2.72M100
Change in cash2.70M690.3K-16.0M-4.03M22.4M100

Open Financials

Filings

FilingDateTypeFiled with
Notification of cessation of securities - CHMOct 30, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 29, 2026Meeting noticeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Ceasing to be a substantial holder for CHMOct 8, 2026Ownership change noticeASX
Notice of initial substantial holder for CHMOct 6, 2026Ownership change noticeASX
Final Director's Interest Notice - LROct 5, 2026List of directorsASX
Final Director's Interest Notice - BGOct 5, 2026List of directorsASX
Initial Director's Interest Notice - RMOct 5, 2026List of directorsASX
FY2026 Annual Report, creditor update and Board changesSep 30, 2026Annual reportASX
All 128 filings
FilingDateTypeFiled with
Application for quotation of securities - CHMSep 29, 2026FinancingASX
Application for quotation of securities - CHMSep 21, 2026FinancingASX
Application for quotation of securities - CHMSep 3, 2026FinancingASX
Appendix 4E and Preliminary Final ReportAug 31, 2026ResultsASX
Application for quotation of securities - CHMAug 27, 2026FinancingASX
Application for quotation of securities - CHMAug 20, 2026FinancingASX
CHM ceases enrolment in Phase 1 trial and Company updateAug 18, 2026Operations updateASX
Trading HaltAug 16, 2026Trading halt or suspensionASX
Application for quotation of securities - CHMAug 6, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 31, 2026Quarterly reportASX
Chimeric receives $1.62M advance on FY26 R&D tax incentiveJul 29, 2026FinancingASX
Investor PresentationJul 27, 2026Other filingsASX
CHM CDH17 Phase 1 clinical trial update - New DL 3 dataJul 15, 2026Operations updateASX
Appointment of Financial Adviser for Strategic ReviewJun 30, 2026Other filingsASX
CHM announces positive Phase 1/2 data at ASCOMay 31, 2026Other filingsASX
Consolidation/Split - CHMMar 18, 2026Other filingsASX
Chimeric receives $1.8 M advance on FY26 R&D tax incentiveMar 1, 2026FinancingASX
Half Year Report and Appendix 4D 31 December 2025Feb 27, 2026Interim reportASX
Portfolio streamlined - return of CHM CLTX to City of HopeFeb 26, 2026Operations updateASX
Funding and EGM updateFeb 24, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 27, 2026Quarterly reportASX
$8.4 M funding to drive CHM CDH17 and resignation of CMODec 22, 2025FinancingASX
Trading HaltDec 18, 2025Trading halt or suspensionASX
CDH17 granted FDA Orphan Drug Designation for Gastric CancerDec 7, 2025Operations updateASX
CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVENov 23, 2025FinancingASX
75% disease control observed in CHM CDH17 trialNov 12, 2025Other filingsASX
CHM CORE NK Combination Phase 1b trial updateNov 12, 2025Operations updateASX
Pause in TradingNov 12, 2025Trading halt or suspensionASX
Response to ASX Query LetterNov 6, 2025Explanation requestASX
Additional complete responses in CHM CORE-NK Phase 1b trialOct 2, 2025Other filingsASX
Disease control and tumour shrinkage observed in CHM CDH17Sep 28, 2025Operations updateASX
Appendix 4E and Annual ReportAug 29, 2025Annual reportASX
CHM CDH17 Clinical Trial UpdateAug 3, 2025Operations updateASX
Chimeric receives $2.5 M advance on FY25 R&D tax incentiveJun 10, 2025Other filingsASX
CHM CDH17 receives FDA Fast TrackJun 4, 2025Operations updateASX
CHM CDH17 ADVANCES TO DOSE LEVEL 2May 20, 2025Operations updateASX
$6.6 million Placement to advance clinical trial pipelineMay 20, 2025FinancingASX
ADVENT-AML Phase 1B clinical trial updateMay 15, 2025Other filingsASX
Completion of Entitlement OfferApr 24, 2025FinancingASX
ProspectusMar 17, 2025Offer documentASX
Entitlement Offer to raise approximately $3.2 millionMar 17, 2025FinancingASX
Reinstatement to QuotationMar 4, 2025Trading halt or suspensionASX
Chimeric announces intention to undertake Entitlement OfferMar 4, 2025FinancingASX
Suspension from QuotationMar 2, 2025Trading halt or suspensionASX
Half Year Report and Appendix 4D 31 December 2024Feb 28, 2025Interim reportASX
$4.0m Non-Dilutionary FundingFeb 27, 2025Other filingsASX
Phase 1B CHM CORE-NK trial advances to newly diagnosed AMLDec 15, 2024Operations updateASX
Chimeric receives $4.17m R&D tax incentiveNov 27, 2024ResultsASX
AGM Presentation and CEO AppointmentNov 11, 2024Meeting outcomeASX
Reinstatement to Official QuotationOct 21, 2024Trading halt or suspensionASX
$5 million Placement to progress CHM CDH17 trialOct 21, 2024FinancingASX
AML patient achieves Complete Response in CHM CORE-NK trialOct 6, 2024Operations updateASX
Appendix 4E and Preliminary Final ReportAug 30, 2024ResultsASX
First patient dosed in Phase 1/2 trial of CHM CDH17Aug 28, 2024Other filingsASX
First patient enrolled in CHM CDH17 Phase 1/2 clinical trialJul 22, 2024Operations updateASX
Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDAJun 4, 2024Operations updateASX
Chimeric opens CHM CDH17 Phase 1/2 trialMay 22, 2024Operations updateASX
CHM CDH17 Phase 1/2 clinical trial approved for initiationMay 19, 2024Operations updateASX
Resignation of CEO and Managing DirectorMay 1, 2024Management or board changeASX
Clinical milestones for 2024 & 2023 successes highlightedMar 13, 2024Operations updateASX
Half Yearly Report and AccountsFeb 28, 2024Interim reportASX
1st patient treated in ADVENT-AML Phase 1b clinical trialFeb 7, 2024Other filingsASX
Placement of Entitlement Offer ShortfallJan 18, 2024FinancingASX
ADVENT-AML Phase 1B clinical trial open to enrolmentJan 14, 2024Operations updateASX
CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVEJan 9, 2024FinancingASX
Positive in vitro data for CHM 1301 CAR NK cellsNov 22, 2023Other filingsASX
1st patient dosed in Phase 1b recurrent glioblastoma trialNov 1, 2023Operations updateASX
FDA clearance of IND for CHM 2101Oct 30, 2023Other filingsASX
Entitlement Offer to raise approximately $10 millionOct 24, 2023FinancingASX
New data for Phase 1A CLTX CAR T brain cancer clinical trialOct 22, 2023Other filingsASX
Agreement with MD Anderson for Phase 1B CHM 0201 AML studySep 12, 2023Other filingsASX
Dosing completion in Phase 1A brain cancer clinical trialAug 28, 2023Other filingsASX
Chimeric to receive A$4.4 million introduction feeAug 16, 2023Other filingsASX
Positive data - CHM 0301 next-gen armoured NK cell platformAug 14, 2023Other filingsASX
CHM secures up to A$12.6m through SPP and placementsJun 23, 2023FinancingASX
Share purchase plan completedJun 23, 2023FinancingASX
Launch of new Phase 1B Glioblastoma clinical trialJun 4, 2023Other filingsASX
SPP offer documents issued to shareholdersMay 22, 2023Offer documentASX
BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPPMay 15, 2023FinancingASX
New CLTX CAR technology patent protection in India & IsraelApr 28, 2023Other filingsASX
Phase 1B brain cancer clinical trial approved for initiationApr 25, 2023Other filingsASX
CHM 1101 GBM Abstract Accepted for ASCO 2023 PresentationApr 3, 2023Other filingsASX
Positive pre-IND meeting with FDA for Phase 1 CAR T studyMar 20, 2023Other filingsASX
Fourth dose cohort initiated in CHM 1101 Phase 1 trialMar 2, 2023Other filingsASX
Appendix 4D and Half Year ReportFeb 28, 2023Interim reportASX
CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVEFeb 14, 2023Other filingsASX
Follow up period completed for 3rd cohort in CHM 1101 trialJan 22, 2023Other filingsASX
Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trialDec 21, 2022Other filingsASX
Exclusive license agreement with CWRU for CORE-NK platformNov 20, 2022Other filingsASX
Patent received in Japan for CLTX CAR technologyAug 2, 2022Other filingsASX
Licenses viral vector technology from Penn for CDH17Jun 28, 2022Other filingsASX
A$30 million Equity Placement Agreement with L1 CapitalJun 9, 2022FinancingASX
Strategic manufacturing partnership with WuXi ATUApr 12, 2022Other filingsASX
Security Class Reinstatement to Quotation CHMOMar 27, 2022Trading halt or suspensionASX
CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCERMar 23, 2022Other filingsASX
Completion of retail component of Entitlement OfferMar 22, 2022FinancingASX
Security Class Suspension from Quotation CHMOMar 20, 2022Trading halt or suspensionASX
Final Results in Phase 1 Trial of CORE NK PlatformMar 6, 2022Other filingsASX
CHIMERIC PARTNERS WITH BE THE MATCH BIOTHERAPIESMar 4, 2022Other filingsASX
Successful completion of Institutional Entitlement OfferFeb 22, 2022FinancingASX
Entitlement Offer to raise approximately $18.1 millionFeb 21, 2022FinancingASX
Encouraging data from 2nd dose cohort in CLTX CAR T trialFeb 7, 2022Other filingsASX
Sponsored Research Agreement with University of PennsylvaniaJan 31, 2022Other filingsASX
Chimeric receives US patent covering CLTX CAR technologyJan 26, 2022Other filingsASX
Transformative Portfolio Expansion PresentationNov 30, 2021Other filingsASX
CLTX CAR T data shows regional control of tumour recurrenceNov 21, 2021Other filingsASX
CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATANov 14, 2021Other filingsASX
FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIALOct 21, 2021Other filingsASX
European patent granted for CLTX technology used in CHM 1101Sep 23, 2021Other filingsASX
Partnership with OncoBay Clinical to advance CHM 1101Sep 2, 2021Other filingsASX
Preliminary Final ReportAug 31, 2021ResultsASX
Chimeric Appoints Jennifer Chow as CEO & MDAug 30, 2021Other filingsASX
IND clearance received from US FDA for CHM 1101Aug 19, 2021Other filingsASX
Chimeric licenses novel solid tumor CAR T therapy from PennJul 27, 2021Other filingsASX
Second Dose Cohort Initiated in CLTX CAR T Phase 1 TrialMay 23, 2021Other filingsASX
Appendix 4C - quarterlyApr 23, 2021Quarterly reportASX
Successful Completion of First Patient Cohort Phase 1 TrialApr 21, 2021Other filingsASX
Successful Completion of Dosing in First Patient CohortMar 17, 2021Other filingsASX

Open Filings

Cap table

Built by 6ix from Chimeric Therapeutics Limited’s releases · as of Jul 31, 2026

Common shares
147,461,982
Fully diluted
147,461,982

Fully diluted

LineShares
Common shares147,461,982

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 2026147,461,982

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Agathe BourgogneHead of Manufacturing · Since at least Nov 5, 2026
Bradley GloverNon-executive Chair · Since at least Nov 5, 2026
Lesley RusselNon-Executive Director · Since at least Nov 5, 2026
Miles PrinceNon-Executive Director · Since at least Nov 5, 2026
Philip HainsNon-Executive Director · Since at least Nov 4, 2026
Rebecca McQualterChief Executive Officer · Since at least Apr 21, 2026
Stephanie H AstrowChief Scientific Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Chimeric Therapeutics Limited.